Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market 2021 by Company, Regions, Type and Application, Forecast to 2026

  • receipt Report ID : 212895
  • calendar_today Published On: Apr, 2021
  • file_copy Pages: 156
  • list Pharmaceuticals and Healthcare
Buy @ $3500

The Recurrent Glioblastoma Multiforme (GBM) Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest research, the global Recurrent Glioblastoma Multiforme (GBM) Treatment size is estimated to be USD xx million in 2026 from USD xx million in 2020, with a change XX% between 2020 and 2021. The global Recurrent Glioblastoma Multiforme (GBM) Treatment market size is expected to grow at a CAGR of xx% for the next five years.

Market segmentation

Recurrent Glioblastoma Multiforme (GBM) Treatment market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers

Oral Medications

Temozolomide

Radiosensitizers

Nitrosoureas Drugs

Radiation Therapy

Chemotherapy

Market segment by Application, can be divided into

Hospitals

Clinics

Ambulatory Surgical Centers

Market segment by players, this report covers

Astrazeneca

Roche

GlaxoSmithKline

Merck

Pfizer

AngioChem

Vascular Biogeneics

Market segment by regions, regional analysis covers

North America (United States, Canada, and Mexico)

Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)

South America (Brazil, Argentina, Rest of South America)

Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 12 chapters:

Chapter 1, to describe Recurrent Glioblastoma Multiforme (GBM) Treatment product scope, market overview, market opportunities, market driving force and market risks.

Chapter 2, to profile the top players of Recurrent Glioblastoma Multiforme (GBM) Treatment, with revenue, gross margin and global market share of Recurrent Glioblastoma Multiforme (GBM) Treatment from 2019 to 2021.

Chapter 3, the Recurrent Glioblastoma Multiforme (GBM) Treatment competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.

Chapter 4 and 5, to segment the market size by type and application, with revenue and growth rate by type, application, from 2016 to 2026.

Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2016 to 2021.and Recurrent Glioblastoma Multiforme (GBM) Treatment market forecast, by regions, type and application, with revenue, from 2021 to 2026.

Chapter 11 and 12, to describe Recurrent Glioblastoma Multiforme (GBM) Treatment research findings and conclusion, appendix and data source.

Frequently Asked Questions

The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.

Market is segmented on the basis:

  • By Type
  • By Application
  • By Region
  • By Country
  • By Manufacturer

The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.

The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.

1 Market Overview

1.1 Product Overview and Scope of Recurrent Glioblastoma Multiforme (GBM) Treatment

1.2 Classification of Recurrent Glioblastoma Multiforme (GBM) Treatment by Type

1.2.1 Overview: Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type: 2020 Versus 2021 Versus 2026

1.2.2 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue Market Share by Type in 2020

1.2.3 Oral Medications

1.2.4 Temozolomide

1.2.5 Radiosensitizers

1.2.6 Nitrosoureas Drugs

1.2.7 Radiation Therapy

1.2.8 Chemotherapy

1.3 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market by Application

1.3.1 Overview: Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application: 2020 Versus 2021 Versus 2026

1.3.2 Hospitals

1.3.3 Clinics

1.3.4 Ambulatory Surgical Centers

1.4 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size & Forecast

1.5 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size and Forecast by Region

1.5.1 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Region: 2016 VS 2021 VS 2026

1.5.2 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Region, (2016-2021)

1.5.3 North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size and Prospect (2016-2026)

1.5.4 Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size and Prospect (2016-2026)

1.5.5 Asia-Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size and Prospect (2016-2026)

1.5.6 South America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size and Prospect (2016-2026)

1.5.7 Middle East and Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size and Prospect (2016-2026)

1.6 Market Drivers, Restraints and Trends

1.6.1 Recurrent Glioblastoma Multiforme (GBM) Treatment Market Drivers

1.6.2 Recurrent Glioblastoma Multiforme (GBM) Treatment Market Restraints

1.6.3 Recurrent Glioblastoma Multiforme (GBM) Treatment Trends Analysis

2 Company Profiles

2.1 Astrazeneca

2.1.1 Astrazeneca Details

2.1.2 Astrazeneca Major Business

2.1.3 Astrazeneca Recurrent Glioblastoma Multiforme (GBM) Treatment Product and Solutions

2.1.4 Astrazeneca Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue, Gross Margin and Market Share (2019-2021)

2.1.5 Astrazeneca Recent Developments and Future Plans

2.2 Roche

2.2.1 Roche Details

2.2.2 Roche Major Business

2.2.3 Roche Recurrent Glioblastoma Multiforme (GBM) Treatment Product and Solutions

2.2.4 Roche Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue, Gross Margin and Market Share (2019-2021)

2.2.5 Roche Recent Developments and Future Plans

2.3 GlaxoSmithKline

2.3.1 GlaxoSmithKline Details

2.3.2 GlaxoSmithKline Major Business

2.3.3 GlaxoSmithKline Recurrent Glioblastoma Multiforme (GBM) Treatment Product and Solutions

2.3.4 GlaxoSmithKline Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue, Gross Margin and Market Share (2019-2021)

2.3.5 GlaxoSmithKline Recent Developments and Future Plans

2.4 Merck

2.4.1 Merck Details

2.4.2 Merck Major Business

2.4.3 Merck Recurrent Glioblastoma Multiforme (GBM) Treatment Product and Solutions

2.4.4 Merck Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue, Gross Margin and Market Share (2019-2021)

2.4.5 Merck Recent Developments and Future Plans

2.5 Pfizer

2.5.1 Pfizer Details

2.5.2 Pfizer Major Business

2.5.3 Pfizer Recurrent Glioblastoma Multiforme (GBM) Treatment Product and Solutions

2.5.4 Pfizer Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue, Gross Margin and Market Share (2019-2021)

2.5.5 Pfizer Recent Developments and Future Plans

2.6 AngioChem

2.6.1 AngioChem Details

2.6.2 AngioChem Major Business

2.6.3 AngioChem Recurrent Glioblastoma Multiforme (GBM) Treatment Product and Solutions

2.6.4 AngioChem Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue, Gross Margin and Market Share (2019-2021)

2.6.5 AngioChem Recent Developments and Future Plans

2.7 Vascular Biogeneics

2.7.1 Vascular Biogeneics Details

2.7.2 Vascular Biogeneics Major Business

2.7.3 Vascular Biogeneics Recurrent Glioblastoma Multiforme (GBM) Treatment Product and Solutions

2.7.4 Vascular Biogeneics Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue, Gross Margin and Market Share (2019-2021)

2.7.5 Vascular Biogeneics Recent Developments and Future Plans

3 Market Competition, by Players

3.1 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue and Share by Players (2019-2021)

3.2 Market Concentration Rate

3.2.1 Top 3 Recurrent Glioblastoma Multiforme (GBM) Treatment Players Market Share

3.2.2 Top 10 Recurrent Glioblastoma Multiforme (GBM) Treatment Players Market Share

3.2.3 Market Competition Trend

3.3 Recurrent Glioblastoma Multiforme (GBM) Treatment Players Head Office, Products and Services Provided

3.4 Mergers & Acquisitions

3.5 New Entrants and Expansion Plans

4 Market Size Segment by Type

4.1 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue and Market Share by Type (2016-2021)

4.2 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Forecast by Type (2021-2026)

5 Market Size Segment by Application

5.1 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue Market Share by Application (2016-2021)

5.2 Recurrent Glioblastoma Multiforme (GBM) Treatment Market Forecast by Application (2021-2026)

6 North America by Country, by Type, and by Application

6.1 North America Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue by Type (2016-2026)

6.2 North America Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue by Application (2016-2026)

6.3 North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Country

6.3.1 North America Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue by Country (2016-2026)

6.3.2 United States Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size and Forecast (2016-2026)

6.3.3 Canada Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size and Forecast (2016-2026)

6.3.4 Mexico Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size and Forecast (2016-2026)

7 Europe by Country, by Type, and by Application

7.1 Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue by Type (2016-2026)

7.2 Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue by Application (2016-2026)

7.3 Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Country

7.3.1 Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue by Country (2016-2026)

7.3.2 Germany Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size and Forecast (2016-2026)

7.3.3 France Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size and Forecast (2016-2026)

7.3.4 United Kingdom Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size and Forecast (2016-2026)

7.3.5 Russia Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size and Forecast (2016-2026)

7.3.6 Italy Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size and Forecast (2016-2026)

8 Asia-Pacific by Region, by Type, and by Application

8.1 Asia-Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue by Type (2016-2026)

8.2 Asia-Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue by Application (2016-2026)

8.3 Asia-Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Region

8.3.1 Asia-Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue by Region (2016-2026)

8.3.2 China Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size and Forecast (2016-2026)

8.3.3 Japan Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size and Forecast (2016-2026)

8.3.4 South Korea Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size and Forecast (2016-2026)

8.3.5 India Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size and Forecast (2016-2026)

8.3.6 Southeast Asia Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size and Forecast (2016-2026)

8.3.7 Australia Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size and Forecast (2016-2026)

9 South America by Country, by Type, and by Application

9.1 South America Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue by Type (2016-2026)

9.2 South America Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue by Application (2016-2026)

9.3 South America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Country

9.3.1 South America Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue by Country (2016-2026)

9.3.2 Brazil Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size and Forecast (2016-2026)

9.3.3 Argentina Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size and Forecast (2016-2026)

10 Middle East & Africa by Country, by Type, and by Application

10.1 Middle East & Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue by Type (2016-2026)

10.2 Middle East & Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue by Application (2016-2026)

10.3 Middle East & Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Country

10.3.1 Middle East & Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue by Country (2016-2026)

10.3.2 Turkey Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size and Forecast (2016-2026)

10.3.3 Saudi Arabia Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size and Forecast (2016-2026)

10.3.4 UAE Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size and Forecast (2016-2026)

11 Research Findings and Conclusion

12 Appendix

12.1 Methodology

12.2 Research Process and Data Source

12.3 Disclaimer

List of Tables

Table 1. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue by Type, (USD Million), 2020 VS 2021 VS 2026

Table 2. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue by Application, (USD Million), 2020 VS 2021 VS 2026

Table 3. Global Market Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)

Table 4. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue (USD Million) by Region (2016-2021)

Table 5. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue Market Share by Region (2021-2026)

Table 6. Astrazeneca Corporate Information, Head Office, and Major Competitors

Table 7. Astrazeneca Major Business

Table 8. Astrazeneca Recurrent Glioblastoma Multiforme (GBM) Treatment Product and Solutions

Table 9. Astrazeneca Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 10. Roche Corporate Information, Head Office, and Major Competitors

Table 11. Roche Major Business

Table 12. Roche Recurrent Glioblastoma Multiforme (GBM) Treatment Product and Solutions

Table 13. Roche Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 14. GlaxoSmithKline Corporate Information, Head Office, and Major Competitors

Table 15. GlaxoSmithKline Major Business

Table 16. GlaxoSmithKline Recurrent Glioblastoma Multiforme (GBM) Treatment Product and Solutions

Table 17. GlaxoSmithKline Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 18. Merck Corporate Information, Head Office, and Major Competitors

Table 19. Merck Major Business

Table 20. Merck Recurrent Glioblastoma Multiforme (GBM) Treatment Product and Solutions

Table 21. Merck Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 22. Pfizer Corporate Information, Head Office, and Major Competitors

Table 23. Pfizer Major Business

Table 24. Pfizer Recurrent Glioblastoma Multiforme (GBM) Treatment Product and Solutions

Table 25. Pfizer Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 26. AngioChem Corporate Information, Head Office, and Major Competitors

Table 27. AngioChem Major Business

Table 28. AngioChem Recurrent Glioblastoma Multiforme (GBM) Treatment Product and Solutions

Table 29. AngioChem Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 30. Vascular Biogeneics Corporate Information, Head Office, and Major Competitors

Table 31. Vascular Biogeneics Major Business

Table 32. Vascular Biogeneics Recurrent Glioblastoma Multiforme (GBM) Treatment Product and Solutions

Table 33. Vascular Biogeneics Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 34. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue (USD Million) by Players (2019-2021)

Table 35. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue Share by Players (2019-2021)

Table 36. Breakdown of Recurrent Glioblastoma Multiforme (GBM) Treatment by Company Type (Tier 1, Tier 2 and Tier 3)

Table 37. Recurrent Glioblastoma Multiforme (GBM) Treatment Players Head Office, Products and Services Provided

Table 38. Recurrent Glioblastoma Multiforme (GBM) Treatment Mergers & Acquisitions in the Past Five Years

Table 39. Recurrent Glioblastoma Multiforme (GBM) Treatment New Entrants and Expansion Plans

Table 40. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue (USD Million) by Type (2016-2021)

Table 41. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue Share by Type (2016-2021)

Table 42. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue Forecast by Type (2021-2026)

Table 43. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue by Application (2016-2021)

Table 44. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue Forecast by Application (2021-2026)

Table 45. North America Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue by Type (2016-2021) & (USD Million)

Table 46. North America Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue by Type (2021-2026) & (USD Million)

Table 47. North America Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue by Application (2016-2021) & (USD Million)

Table 48. North America Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue by Application (2021-2026) & (USD Million)

Table 49. North America Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue by Country (2016-2021) & (USD Million)

Table 50. North America Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue by Country (2021-2026) & (USD Million)

Table 51. Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue by Type (2016-2021) & (USD Million)

Table 52. Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue by Type (2021-2026) & (USD Million)

Table 53. Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue by Application (2016-2021) & (USD Million)

Table 54. Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue by Application (2021-2026) & (USD Million)

Table 55. Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue by Country (2016-2021) & (USD Million)

Table 56. Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue by Country (2021-2026) & (USD Million)

Table 57. Asia-Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue by Type (2016-2021) & (USD Million)

Table 58. Asia-Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue by Type (2021-2026) & (USD Million)

Table 59. Asia-Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue by Application (2016-2021) & (USD Million)

Table 60. Asia-Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue by Application (2021-2026) & (USD Million)

Table 61. Asia-Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue by Region (2016-2021) & (USD Million)

Table 62. Asia-Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue by Region (2021-2026) & (USD Million)

Table 63. South America Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue by Type (2016-2021) & (USD Million)

Table 64. South America Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue by Type (2021-2026) & (USD Million)

Table 65. South America Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue by Application (2016-2021) & (USD Million)

Table 66. South America Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue by Application (2021-2026) & (USD Million)

Table 67. South America Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue by Country (2016-2021) & (USD Million)

Table 68. South America Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue by Country (2021-2026) & (USD Million)

Table 69. Middle East & Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue by Type (2016-2021) & (USD Million)

Table 70. Middle East & Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue by Type (2021-2026) & (USD Million)

Table 71. Middle East & Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue by Application (2016-2021) & (USD Million)

Table 72. Middle East & Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue by Application (2021-2026) & (USD Million)

Table 73. Middle East & Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue by Country (2016-2021) & (USD Million)

Table 74. Middle East & Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue by Country (2021-2026) & (USD Million)

List of Figures

Figure 1. Recurrent Glioblastoma Multiforme (GBM) Treatment Picture

Figure 2. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue Market Share by Type in 2020

Figure 3. Oral Medications

Figure 4. Temozolomide

Figure 5. Radiosensitizers

Figure 6. Nitrosoureas Drugs

Figure 7. Radiation Therapy

Figure 8. Chemotherapy

Figure 9. Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue Market Share by Application in 2020

Figure 10. Hospitals Picture

Figure 11. Clinics Picture

Figure 12. Ambulatory Surgical Centers Picture

Figure 13. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue, (USD Million): 2020 VS 2021 VS 2026

Figure 14. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue and Forecast (2016-2026) & (USD Million)

Figure 15. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue Market Share by Region (2016-2026)

Figure 16. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue Market Share by Region in 2020

Figure 17. North America Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue (USD Million) and Growth Rate (2016-2026)

Figure 18. Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue (USD Million) and Growth Rate (2016-2026)

Figure 19. Asia-Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue (USD Million) and Growth Rate (2016-2026)

Figure 20. South America Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue (USD Million) and Growth Rate (2016-2026)

Figure 21. Middle East and Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue (USD Million) and Growth Rate (2016-2026)

Figure 22. Recurrent Glioblastoma Multiforme (GBM) Treatment Market Drivers

Figure 23. Recurrent Glioblastoma Multiforme (GBM) Treatment Market Restraints

Figure 24. Recurrent Glioblastoma Multiforme (GBM) Treatment Market Trends

Figure 25. Astrazeneca Recent Developments and Future Plans

Figure 26. Roche Recent Developments and Future Plans

Figure 27. GlaxoSmithKline Recent Developments and Future Plans

Figure 28. Merck Recent Developments and Future Plans

Figure 29. Pfizer Recent Developments and Future Plans

Figure 30. AngioChem Recent Developments and Future Plans

Figure 31. Vascular Biogeneics Recent Developments and Future Plans

Figure 32. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue Share by Players in 2020

Figure 33. Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

Figure 34. Global Top 3 Players Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue Market Share in 2020

Figure 35. Global Top 10 Players Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue Market Share in 2020

Figure 36. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)

Figure 37. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue Share by Type in 2020

Figure 38. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share Forecast by Type (2021-2026)

Figure 39. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue Share by Application in 2020

Figure 40. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share Forecast by Application (2021-2026)

Figure 41. North America Recurrent Glioblastoma Multiforme (GBM) Treatment Sales Market Share by Type (2016-2026)

Figure 42. North America Recurrent Glioblastoma Multiforme (GBM) Treatment Sales Market Share by Application (2016-2026)

Figure 43. North America Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue Market Share by Country (2016-2026)

Figure 44. United States Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 45. Canada Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 46. Mexico Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 47. Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Sales Market Share by Type (2016-2026)

Figure 48. Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Sales Market Share by Application (2016-2026)

Figure 49. Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue Market Share by Country (2016-2026)

Figure 50. Germany Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 51. France Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 52. United Kingdom Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 53. Russia Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 54. Italy Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 55. Asia-Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Sales Market Share by Type (2016-2026)

Figure 56. Asia-Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Sales Market Share by Application (2016-2026)

Figure 57. Asia-Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue Market Share by Region (2016-2026)

Figure 58. China Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 59. Japan Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 60. South Korea Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 61. India Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 62. Southeast Asia Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 63. Australia Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 64. South America Recurrent Glioblastoma Multiforme (GBM) Treatment Sales Market Share by Type (2016-2026)

Figure 65. South America Recurrent Glioblastoma Multiforme (GBM) Treatment Sales Market Share by Application (2016-2026)

Figure 66. South America Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue Market Share by Country (2016-2026)

Figure 67. Brazil Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 68. Argentina Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 69. Middle East and Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Sales Market Share by Type (2016-2026)

Figure 70. Middle East and Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Sales Market Share by Application (2016-2026)

Figure 71. Middle East and Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue Market Share by Country (2016-2026)

Figure 72. Turkey Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 73. Saudi Arabia Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 74. UAE Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 75. Methodology

Figure 76. Research Process and Data Source

shopping_cart License Type

Buy Now

email Quick Contact

tag_faces Our Clients

help Need Help?

Please contact directly on our US and India numbers

+1-201-465-4211

Please feel free to write an email to us or to use our electronic ticketing system.

sales@marketsandresearch.biz